Editas Medicine, Inc.
EDIT$191M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE226 employees
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
EDIT News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
No drugs found in this phase.
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply